A Single-arm, Open-label Phase 2 Study of Nirogacestat in Adult Japanese Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Latest Information Update: 23 Sep 2026
At a glance
- Drugs Nirogacestat (Primary)
- Indications Fibroma
- Focus Therapeutic Use
- Sponsors SpringWorks Therapeutics
Most Recent Events
- 29 Jun 2026 Planned End Date changed from 31 Oct 2029 to 9 Oct 2029.
- 29 Jun 2026 Planned primary completion date changed from 31 Mar 2027 to 28 May 2027.
- 06 Apr 2026 Planned End Date changed from 31 Dec 2030 to 31 Oct 2029.